Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RATE: Reduced anticoagulation targets in extracorporeal life support
NL-OMON59516Phase 3Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2021
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of heparin and low molecular weight heparin calcium (3 arms), sponsored by University Medical Center Groningen. Primary endpoints: Composite primary endpoint, Major bleeding including hemorrhagic stroke and 2 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
heparinlow molecular weight heparin calcium
Beyond the preview
Go deeper on NL-OMON59516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59516.